Ventyx Biosciences, Inc.

The momentum for this stock is not very good. Ventyx Biosciences, Inc. has good growth characteristics. Ventyx Biosciences, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Ventyx Biosciences, Inc..

News

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of "Moderate Buy" from Analysts

Ticker Report Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat.com...\n more…

Ventyx Biosciences announces first patient dosed in Phase 2a trial of VTX3232

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Globe Newswire Results from this trial are expected in 2025SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ( Ventyx ), a clinical-stage biopharmaceutical company focused on...\n more…

Ventyx Biosciences CFO departs

Seeking Alpha - Healthcare Ventyx Biosciences CFO departs...\n more…

Ventyx Biosciences announces departure of CFO Auster

Ventyx Biosciences Announces Departure of Chief Financial Officer

Globe Newswire SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ( Ventyx ), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...\n more…